China approves Merck antiviral as it battles COVID-19 wave


China’s top drug regulator said Friday that it approved Merck & Co.’s Molnupiravir for emergency use on Thursday, as the country grapples with waves of infections after Beijing abruptly reversed its stringent Covid-19 restrictions earlier this month.

The National Medical Products Administration said it is requiring the approval holder to continue relevant research, complete conditional requirements and submit follow-up research results in a timely manner, according to a statement posted on its website Friday.

Write to Singapore Editors at

Corrections & Amplifications

This item was corrected at 0856 GMT to reflect China’s top drug regulator said it approved Merck & Co.’s Molnupiravir for emergency use on Thursday. The original version incorrectly said the approval came on Wednesday in the first paragraph.

This article was originally published by Read the original article here.

Previous article: It should be much easier to know how much a job pays in 2023
Next articleEconomic Report: U.K. house prices see longest losing streak since global financial crisis, lender says


Please enter your comment!
Please enter your name here